{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:16:45Z","timestamp":1794961005404,"version":"4.9.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ygyno.2023.01.038","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T14:13:44Z","timestamp":1677248024000},"page":"83-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["The potential of RAS\/RAF\/MEK\/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"171","author":[{"given":"C.S.E.","family":"Hendrikse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.M.","family":"Theelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"Westgeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.A.","family":"Boere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.J.","family":"Thijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.B.","family":"Ottevanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"van de Stolpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lambrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.M.","family":"Bekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.J.","family":"Piek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2023.01.038_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2023.01.038_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejcsup.2020.02.001","article-title":"Morphological and molecular heterogeneity of epithelial ovarian cancer: therapeutic implications","volume":"15","author":"Romero","year":"2020","journal-title":"EJC Suppl."},{"issue":"4","key":"10.1016\/j.ygyno.2023.01.038_bb0015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.ygyno.2023.01.038_bb0020","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.hoc.2018.07.010","article-title":"Diagnosis and treatment of ovarian Cancer","volume":"32","author":"Orr","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"1","key":"10.1016\/j.ygyno.2023.01.038_bb0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.ygyno.2023.01.038_bb0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000479006","article-title":"Ovarian Cancer: a heterogeneous disease","volume":"85","author":"Kossai","year":"2018","journal-title":"Pathobiology."},{"issue":"5","key":"10.1016\/j.ygyno.2023.01.038_bb0040","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"issue":"22","key":"10.1016\/j.ygyno.2023.01.038_bb0045","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: a new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.ygyno.2023.01.038_bb0050","first-page":"153","article-title":"Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions","volume":"22","author":"Pearson","year":"2001","journal-title":"Endocr. Rev."},{"issue":"5973","key":"10.1016\/j.ygyno.2023.01.038_bb0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/310147a0","article-title":"Epidermal growth factor stimulates guanine nucleotide binding activity and phosphorylation of ras oncogene proteins","volume":"310","author":"Kamata","year":"1984","journal-title":"Nature."},{"issue":"34","key":"10.1016\/j.ygyno.2023.01.038_bb0060","doi-asserted-by":"crossref","first-page":"23850","DOI":"10.1074\/jbc.274.34.23850","article-title":"M-Ras\/R-Ras3, a transforming ras protein regulated by Sos1, GRF1, and p120 Ras GTPase-activating protein, interacts with the putative Ras effector AF6","volume":"274","author":"Quilliam","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"6385","key":"10.1016\/j.ygyno.2023.01.038_bb0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/358417a0","article-title":"Raf-1 activates MAP kinase-kinase","volume":"358","author":"Kyriakis","year":"1992","journal-title":"Nature."},{"issue":"7","key":"10.1016\/j.ygyno.2023.01.038_bb0070","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/j.1460-2075.1994.tb06424.x","article-title":"Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1","volume":"13","author":"Alessi","year":"1994","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.ygyno.2023.01.038_bb0075","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1128\/MCB.00569-09","article-title":"Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling","volume":"30","author":"Ritt","year":"2010","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.01.038_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-17-0349","article-title":"Rational approaches for combination therapy strategies targeting the MAP kinase pathway in solid tumors","volume":"17","author":"Tolcher","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.ygyno.2023.01.038_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101618","article-title":"A comprehensive review on MAPK: a promising therapeutic target in cancer","volume":"11","author":"Braicu","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"6","key":"10.1016\/j.ygyno.2023.01.038_bb0090","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"issue":"2","key":"10.1016\/j.ygyno.2023.01.038_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054103","article-title":"Exploiting MEK inhibitor-mediated activation of ER\u03b1 for therapeutic intervention in ER-positive ovarian carcinoma","volume":"8","author":"Hou","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ygyno.2023.01.038_bb0100","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/1078-0432.CCR-15-0534","article-title":"MAPK activation predicts poor outcome and the MEK inhibitor, Selumetinib, reverses antiestrogen resistance in ER-positive high-grade serous ovarian Cancer","volume":"22","author":"Hew","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.ygyno.2023.01.038_bb0105","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-21-4183","article-title":"MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma","volume":"28","author":"Manning-Geist","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ygyno.2023.01.038_bb0110","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41568-018-0076-6","article-title":"A model for RAS mutation patterns in cancers: finding the sweet spot","volume":"18","author":"Li","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2023.01.038_bb0115","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-13-2054","article-title":"Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma","volume":"20","author":"Menzies","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.ygyno.2023.01.038_bb0120","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1158\/1078-0432.CCR-18-0494","article-title":"Phase Ib study of Binimetinib with paclitaxel in patients with platinum-resistant ovarian cancer: final results, potential biomarkers, and extreme responders","volume":"24","author":"Grisham","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2023.01.038_bb0125","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/1078-0432.CCR-14-1814","article-title":"A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1\/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors","volume":"21","author":"Bedard","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2023.01.038_bb0130","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ."},{"key":"10.1016\/j.ygyno.2023.01.038_bb0135","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ."},{"key":"10.1016\/j.ygyno.2023.01.038_bb0140","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"10.1016\/j.ygyno.2023.01.038_bb0145","series-title":"How to Conduct a Meta-Analysis of Proportions in R: A Comprehensive Tutorial","author":"Wang","year":"2018"},{"issue":"30","key":"10.1016\/j.ygyno.2023.01.038_bb0150","doi-asserted-by":"crossref","first-page":"21383","DOI":"10.18632\/oncotarget.25109","article-title":"Signature program: a platform of basket trials","volume":"9","author":"Slosberg","year":"2018","journal-title":"Oncotarget."},{"issue":"10","key":"10.1016\/j.ygyno.2023.01.038_bb0155","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/annonc\/mdi310","article-title":"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on\/7 days off in patients with advanced, refractory solid tumors","volume":"16","author":"Moore","year":"2005","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2023.01.038_bb0160","article-title":"Phase I dose-finding study of oral ERK1\/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations","volume":"38","author":"Janku","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.01.038_bb0165","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2019.12.002","volume":"156","author":"Arend","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2023.01.038_bb0170","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-12-0742","article-title":"First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK\/RAF inhibitor in patients with solid tumors","volume":"18","author":"Martinez-Garcia","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"32","key":"10.1016\/j.ygyno.2023.01.038_bb0175","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: Binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.038_bb0180","author":"Genentech"},{"issue":"1","key":"10.1016\/j.ygyno.2023.01.038_bb0185","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0090-8258(02)00144-0","article-title":"Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)","volume":"89","author":"Oza","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.01.038_bb0190","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2011.06.019","article-title":"Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study","volume":"123","author":"Bodnar","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2023.01.038_bb0195","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10637-014-0078-5","article-title":"Randomized phase II trial of sorafenib alone or in combination with carboplatin\/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer","volume":"32","author":"Schwandt","year":"2014","journal-title":"Investig. New Drugs"},{"issue":"10324","key":"10.1016\/j.ygyno.2023.01.038_bb0200","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.ygyno.2023.01.038_bb0205","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.01.038_bb0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","article-title":"Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial","volume":"29","author":"Matei","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.038_bb0215","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2019.06.017","article-title":"Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme","volume":"118","author":"Varnier","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"33","key":"10.1016\/j.ygyno.2023.01.038_bb0220","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in patients with tumors with BRAF(V600E) mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.038_bb0225","series-title":"Common terminology criteria for adverse events (CTCAE) version 5.0","author":"National Institutes of Health NCI","year":"2017"},{"issue":"9992","key":"10.1016\/j.ygyno.2023.01.038_bb0230","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet."},{"issue":"149","key":"10.1016\/j.ygyno.2023.01.038_bb0235","doi-asserted-by":"crossref","first-page":"ra84","DOI":"10.1126\/scisignal.2001148","article-title":"BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation","volume":"3","author":"Corcoran","year":"2010","journal-title":"Sci. Signal."},{"issue":"3","key":"10.1016\/j.ygyno.2023.01.038_bb0240","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/AOG.0000000000001867","article-title":"Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian Cancer","volume":"129","author":"Gockley","year":"2017","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.01.038_bb0245","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.038_bb0250","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2016.12.012","article-title":"MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"17","key":"10.1016\/j.ygyno.2023.01.038_bb0255","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"34","key":"10.1016\/j.ygyno.2023.01.038_bb0260","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","article-title":"Combined BRAF and MEK inhibition with Dabrafenib and Trametinib in BRAF V600-mutant colorectal cancer","volume":"33","author":"Corcoran","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.038_bb0265","series-title":"Phase I Study of the Combination of the Dual RAF\/MEK Inhibitor VS-6766 and the FAK Inhibitor Defactinib: Results of Efficacy in Low Grade Serous Ovarian cancer","author":"Banerjee","year":"2021"},{"issue":"3","key":"10.1016\/j.ygyno.2023.01.038_bb0270","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ygyno.2017.06.036","article-title":"Clinical benefit and risk of death with endocrine therapy in ovarian cancer: a comprehensive review and meta-analysis","volume":"146","author":"Paleari","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.01.038_bb0275","series-title":"Successful Implementation of a Novel Trial Model- the Signature Program 2015 American Society of Clinical Oncology Annual Meeting 2015 Chicago, Illinois","author":"Peguero","year":"2015"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823000549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823000549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T20:51:18Z","timestamp":1715806278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823000549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":54,"alternative-id":["S0090825823000549"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.038","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential of RAS\/RAF\/MEK\/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}